ConductScience.org, home

Paper23800114

Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.

Nodin B and 3 others. Diagn Pathol, 2013. Cited by 33 papers, by iCite.

Cite this record

ConductScience Library. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer. Papers, record 23800114. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23800114

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.
PubMed
Journal
Diagn Pathol
PubMed
Year
2013
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
33
iCite
Relative citation ratio, by iCite
0.91
iCite
Revised in PubMed
2021-10-21
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Nodin BBjörn
2Zendehrokh NNooreldin
3Sundström MMagnus
4Jirström KKarin

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
MutationMajor topic
Neoplasms, Glandular and EpithelialMajor topic
Ovarian NeoplasmsMajor topic
Proto-Oncogene ProteinsMajor topic
ras ProteinsMajor topic
Adenocarcinoma, Mucinous
Aged
Biomarkers, Tumor
Carcinoma, Ovarian Epithelial
Female
Humans
Kaplan-Meier Estimate
Middle Aged
Prognosis
Prospective Studies
Proto-Oncogene Proteins p21(ras)

Source PubMed

Download CSV of topics

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121804916RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer.Transl Oncol2011https://conductscience.org/library/papers/21804916PubMed
221716157Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.Pathology2011https://conductscience.org/library/papers/21716157PubMed
33047672KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.Nucleic Acids Res1988https://conductscience.org/library/papers/3047672PubMed
420126258Global regulator SATB1 recruits beta-catenin and regulates T(H)2 differentiation in Wnt-dependent manner.PLoS Biol2010https://conductscience.org/library/papers/20126258PubMed
58429286The Malmo Diet and Cancer Study. Design and feasibility.J Intern Med1993https://conductscience.org/library/papers/8429286PubMed
616806438KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.Gynecol Oncol2006https://conductscience.org/library/papers/16806438PubMed
711444200k-ras mutation may be an early event in mucinous ovarian tumorigenesis.Int J Gynecol Pathol2001https://conductscience.org/library/papers/11444200PubMed
819358724KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.BMC Cancer2009https://conductscience.org/library/papers/19358724PubMed
912644542Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.J Natl Cancer Inst2003https://conductscience.org/library/papers/12644542PubMed
1021571648Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment.Radiographics2011https://conductscience.org/library/papers/21571648PubMed
1122322322Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features.Virchows Arch2012https://conductscience.org/library/papers/22322322PubMed
1215111296Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.Am J Pathol2004https://conductscience.org/library/papers/15111296PubMed
138115781Residual tumor (R) classification and prognosis.Semin Surg Oncol1994https://conductscience.org/library/papers/8115781PubMed
1419542870Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.Am J Surg Pathol2009https://conductscience.org/library/papers/19542870PubMed
1512509763Targeting RAS signalling pathways in cancer therapy.Nat Rev Cancer2003https://conductscience.org/library/papers/12509763PubMed
1622992394Expression of the global regulator SATB1 is an independent factor of poor prognosis in high grade epithelial ovarian cancer.J Ovarian Res2012https://conductscience.org/library/papers/22992394PubMed
1722995373
Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.
Diagn Pathol2012https://conductscience.org/library/papers/22995373PubMed
1821870058Correlation of SATB1 overexpression with the progression of human rectal cancer.Int J Colorectal Dis2012https://conductscience.org/library/papers/21870058PubMed
199662379Tissue microarrays for high-throughput molecular profiling of tumor specimens.Nat Med1998https://conductscience.org/library/papers/9662379PubMed
2017914554Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.Oncol Rep2007https://conductscience.org/library/papers/17914554PubMed

See all 49 referencesDownload CSV of references

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.

PMIDTitleJournalYearIn PapersSource
39522047RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms.J Hematol Oncol2024https://conductscience.org/library/papers/39522047PubMed
37851341Machine learning developed a PI3K/Akt pathway-related signature for predicting prognosis and drug sensitivity in ovarian cancer.Aging (Albany NY)2023https://conductscience.org/library/papers/37851341PubMed
36451660Role of RAS signaling in ovarian cancer.F1000Res2022https://conductscience.org/library/papers/36451660PubMed
34615547Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer.J Ovarian Res2021https://conductscience.org/library/papers/34615547PubMed
34301278Emerging strategies to target RAS signaling in human cancer therapy.J Hematol Oncol2021https://conductscience.org/library/papers/34301278PubMed
33817145Overexpression of RASAL1 Indicates Poor Prognosis and Promotes Invasion of Ovarian Cancer.Open Life Sci2019https://conductscience.org/library/papers/33817145PubMed
32782545Mutation analysis and genomic imbalances of cells found in effusion fluids from patients with ovarian cancer.Oncol Lett2020https://conductscience.org/library/papers/32782545PubMed
32120793Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer.Cancers (Basel)2020https://conductscience.org/library/papers/32120793PubMed
32042390Prevalence of K-RAS mutations and CA125 tumor marker in patients with ovarian carcinoma.Caspian J Intern Med2020https://conductscience.org/library/papers/32042390PubMed
31111275KRAS status is related to histological phenotype in gastric cancer: results from a large multicentre study.Gastric Cancer2019https://conductscience.org/library/papers/31111275PubMed
31009485Arsenite malignantly transforms human prostate epithelial cells in vitro by gene amplification of mutated KRAS.PLoS One2019https://conductscience.org/library/papers/31009485PubMed
28728166Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.Br J Cancer2017https://conductscience.org/library/papers/28728166PubMed
27995550Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.Mol Diagn Ther2017https://conductscience.org/library/papers/27995550PubMed
27893429MicroRNA-595 sensitizes ovarian cancer cells to cisplatin by targeting ABCB1.Oncotarget2016https://conductscience.org/library/papers/27893429PubMed
27231561Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms.Gynecol Oncol Res Pract2015https://conductscience.org/library/papers/27231561PubMed
27048364Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer.J Ovarian Res2016https://conductscience.org/library/papers/27048364PubMed
26631045MicroRNA-613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS.Tumour Biol2016https://conductscience.org/library/papers/26631045PubMed
26170722Endometriosis and ovarian cancer: links, risks, and challenges faced.Int J Womens Health2015https://conductscience.org/library/papers/26170722PubMed
24889043Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.Virchows Arch2014https://conductscience.org/library/papers/24889043PubMed
24848074Ovarian cancer in endometriosis: clinical and molecular aspects.Minerva Ginecol2014https://conductscience.org/library/papers/24848074PubMed

See all 23 cited byDownload CSV of cited by

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23800114

GET https://conductscience.org/api/papers/v1/23800114/references?page=2